The findings from our study and the above-mentioned studies demonstrate the similar effectiveness of ETN, ADA, and tofacitinib when used as first-line targeted therapy in b/tsDMARD-naïve patients with RA. This evidence concerns the gene ADA and rheumatoid arthritis.